Management and Outcomes of Adverse Events Following Immune Checkpoint Inhibitor Treatment in Patients with Hepatocellular Carcinoma
10.52927/jdcr.2025.13.1.65
- Author:
Soon Kyu LEE
1
;
Bo Hyun KIM
Author Information
1. Division of gastroenterology and hepatology, Department of Internal Medicine, Incheon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea
- Publication Type:REVIEW ARTICLE
- From:
Journal of Digestive Cancer Research
2025;13(1):65-73
- CountryRepublic of Korea
- Language:English
-
Abstract:
Hepatocellular carcinoma (HCC), a leading cause of cancer-related mortality, is often diagnosed at an advanced stage. As a result, approximately half of patients with HCC received systemic therapy during the disease course. In recent years, the introduction of immune checkpoint inhibitors (ICIs)—notably, atezolizumab plus bevacizumab and tremelimumab plus durvalumab—has transformed the treatment paradigm for advanced HCC, making them a firstline treatment option. Considering the increasing use of ICIs, understanding the incidence and appropriate management of their adverse events (AEs) is necessary for patient care. Hence, this review summarizes the incidence and management strategies for key immune-related AEs, including liver injury (hepatitis), thyroiditis, colitis, skin rash, and pneumonitis. Additionally, we discuss AEs associated with vascular endothelial growth factor inhibitors, such as hypertension, proteinuria, and bleeding. By thoroughly understanding these treatment-related AEs, the clinical outcomes of patients with HCC undergoing ICI-based therapy may be improved.
